{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:43:04Z","timestamp":1786221784681,"version":"build-2736575974"},"reference-count":161,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R35GM150607"],"award-info":[{"award-number":["R35GM150607"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01AI157975"],"award-info":[{"award-number":["R01AI157975"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Pharmaceutica Sinica B"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.apsb.2026.06.017","type":"journal-article","created":{"date-parts":[[2026,6,13]],"date-time":"2026-06-13T00:08:41Z","timestamp":1781309321000},"page":"4978-4997","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Nanobodies targeting SARS-CoV-2 variants"],"prefix":"10.1016","volume":"16","author":[{"given":"Abhijeet","family":"Roy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5955-1294","authenticated-orcid":false,"given":"Lanying","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.apsb.2026.06.017_bib1","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1038\/nrmicro775","article-title":"SARS-beginning to understand a new virus","volume":"1","author":"Stadler","year":"2003","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2026.06.017_bib2","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1016\/S0140-6736(03)14630-2","article-title":"Epidemiology and cause of severe acute respiratory syndrome (SARS) in Guangdong, people\u2019s Republic of China, in February, 2003","volume":"362","author":"Zhong","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2026.06.017_bib3","doi-asserted-by":"crossref","first-page":"1814","DOI":"10.1056\/NEJMoa1211721","article-title":"Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia","volume":"367","author":"Zaki","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.06.017_bib5","first-page":"157","article-title":"WHO declares COVID-19 a pandemic","volume":"91","author":"Cucinotta","year":"2020","journal-title":"Acta Biomed"},{"key":"10.1016\/j.apsb.2026.06.017_bib6","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1056\/NEJMoa2001017","article-title":"A novel coronavirus from patients with pneumonia in China, 2019","volume":"382","author":"Zhu","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.06.017_bib7","unstructured":"World Health Organization. WHO COVID-19 dashboard [cited April 26, 2026]. Available from: https:\/\/data.who.int\/dashboards\/covid19\/cases."},{"key":"10.1016\/j.apsb.2026.06.017_bib8","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2026.06.017_bib9","doi-asserted-by":"crossref","first-page":"e220","DOI":"10.1136\/bmjspcare-2020-002813","article-title":"Asymptomatic COVID-19 infection: diagnosis, transmission, population characteristics","volume":"14","author":"You","year":"2024","journal-title":"BMJ Support Palliat Care"},{"key":"10.1016\/j.apsb.2026.06.017_bib10","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1093\/emph\/eoac010","article-title":"Mutation rate of SARS-CoV-2 and emergence of mutators during experimental evolution","volume":"10","author":"Amicone","year":"2022","journal-title":"Evol Med Public Health"},{"key":"10.1016\/j.apsb.2026.06.017_bib11","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1186\/s12879-021-06222-4","article-title":"Modes of transmission of SARS-CoV-2 and evidence for preventive behavioral interventions","volume":"21","author":"Zhou","year":"2021","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.apsb.2026.06.017_bib12","first-page":"CD013665","article-title":"Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19","volume":"5","author":"Struyf","year":"2022","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.apsb.2026.06.017_bib13","doi-asserted-by":"crossref","first-page":"9557","DOI":"10.1038\/s41467-025-65239-4","article-title":"Long COVID trajectories in the prospectively followed RECOVER-adult US cohort","volume":"16","author":"Thaweethai","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.017_bib14","doi-asserted-by":"crossref","first-page":"452","DOI":"10.1016\/S0140-6736(22)01214-4","article-title":"Persistence of somatic symptoms after COVID-19 in the Netherlands: an observational cohort study","volume":"400","author":"Ballering","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2026.06.017_bib15","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1177\/01410768211032850","article-title":"Symptoms, complications and management of long COVID: a review","volume":"114","author":"Aiyegbusi","year":"2021","journal-title":"J R Soc Med"},{"key":"10.1016\/j.apsb.2026.06.017_bib16","doi-asserted-by":"crossref","DOI":"10.3389\/fvets.2020.596391","article-title":"An overview of SARS-CoV-2 and animal infection","volume":"7","author":"Mahdy","year":"2020","journal-title":"Front Vet Sci"},{"key":"10.1016\/j.apsb.2026.06.017_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2020.110499","article-title":"Outbreak of COVID-19: an emerging global pandemic threat","volume":"129","author":"Peng","year":"2020","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.apsb.2026.06.017_bib18","article-title":"Infection with the SARS-CoV-2 Delta variant is associated with higher infectious virus loads compared to the alpha variant in both unvaccinated and vaccinated individuals","author":"Luo","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.apsb.2026.06.017_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000029165","article-title":"Omicron SARS-CoV-2 variant of concern: a review on its transmissibility, immune evasion, reinfection, and severity","volume":"101","author":"Mohsin","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.apsb.2026.06.017_bib20","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbadis.2020.165878","article-title":"Insights into SARS-CoV-2 genome, structure, evolution, pathogenesis and therapies: structural genomics approach","volume":"1866","author":"Naqvi","year":"2020","journal-title":"Biochim Biophys Acta Mol Basis Dis"},{"key":"10.1016\/j.apsb.2026.06.017_bib21","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.552909","article-title":"Comparative review of SARS-CoV-2, SARS-CoV, MERS-CoV, and influenza A respiratory viruses","volume":"11","author":"Abdelrahman","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.06.017_bib22","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-021-96626-8","article-title":"A comparative recombination analysis of human coronaviruses and implications for the SARS-CoV-2 pandemic","volume":"11","author":"Pollett","year":"2021","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.06.017_bib23","article-title":"Structural genomic analysis of SARS-CoV-2 and other coronaviruses","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Genet"},{"key":"10.1016\/j.apsb.2026.06.017_bib24","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s13337-020-00642-7","article-title":"Chasing COVID-19 through SARS-CoV-2 spike glycoprotein","volume":"31","author":"Saxena","year":"2020","journal-title":"Virusdisease"},{"key":"10.1016\/j.apsb.2026.06.017_bib25","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1007\/s11427-021-1964-4","article-title":"Overview of SARS-CoV-2 genome-encoded proteins","volume":"65","author":"Bai","year":"2022","journal-title":"Sci China Life Sci"},{"key":"10.1016\/j.apsb.2026.06.017_bib26","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1038\/s41579-021-00630-8","article-title":"Structural biology of SARS-CoV-2 and implications for therapeutic development","volume":"19","author":"Yang","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2026.06.017_bib27","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1038\/s41586-020-2286-9","article-title":"A SARS-CoV-2 protein interaction map reveals targets for drug repurposing","volume":"583","author":"Gordon","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.017_bib28","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.058","article-title":"Structure, function, and antigenicity of the SARS-CoV-2 spike glycoprotein","volume":"181","author":"Walls","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.017_bib29","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1126\/science.abb2507","article-title":"Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation","volume":"367","author":"Wrapp","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.06.017_bib30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1038\/s41586-020-2179-y","article-title":"Structural basis of receptor recognition by SARS-CoV-2","volume":"581","author":"Shang","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.017_bib31","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1038\/s41586-020-2180-5","article-title":"Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor","volume":"581","author":"Lan","year":"2020","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.017_bib32","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/s41422-020-0305-x","article-title":"Inhibition of SARS-CoV-2 (previously 2019-nCoV) infection by a highly potent pan-coronavirus fusion inhibitor targeting its spike protein that harbors a high capacity to mediate membrane fusion","volume":"30","author":"Xia","year":"2020","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2026.06.017_bib33","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1038\/s41401-020-0485-4","article-title":"Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19","volume":"41","author":"Huang","year":"2020","journal-title":"Acta Pharmacol Sin"},{"key":"10.1016\/j.apsb.2026.06.017_bib34","doi-asserted-by":"crossref","first-page":"1586","DOI":"10.1126\/science.abd4251","article-title":"Distinct conformational states of SARS-CoV-2 spike protein","volume":"369","author":"Cai","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.06.017_bib35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-021-00809-8","article-title":"The glycosylation in SARS-CoV-2 and its receptor ACE2","volume":"6","author":"Gong","year":"2021","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.06.017_bib36","doi-asserted-by":"crossref","first-page":"821","DOI":"10.3390\/cells10040821","article-title":"Role of structural and non-structural proteins and therapeutic targets of SARS-CoV-2 for COVID-19","volume":"10","author":"Yadav","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.apsb.2026.06.017_bib37","article-title":"A review on structural, non-structural, and accessory proteins of SARS-CoV-2: highlighting drug target sites","volume":"228","author":"Jahirul","year":"2023","journal-title":"Immunobiology"},{"key":"10.1016\/j.apsb.2026.06.017_bib38","doi-asserted-by":"crossref","first-page":"4725","DOI":"10.1080\/07391102.2020.1861983","article-title":"Structure and dynamics of membrane protein in SARS-CoV-2","volume":"40","author":"Mahtarin","year":"2022","journal-title":"J Biomol Struct Dyn"},{"key":"10.1016\/j.apsb.2026.06.017_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2021.710778","article-title":"Remdesivir strongly binds to RNA-dependent RNA polymerase, membrane protein, and main protease of SARS-CoV-2: indication from molecular modeling and simulations","volume":"12","author":"Khan","year":"2021","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.apsb.2026.06.017_bib40","article-title":"SARS-CoV-2 E protein: pathogenesis and potential therapeutic development","volume":"159","author":"Zhou","year":"2023","journal-title":"Biomed Pharmacother Biomedecine Pharmacother"},{"key":"10.1016\/j.apsb.2026.06.017_bib41","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1007\/s42485-021-00060-3","article-title":"The percentages of SARS-CoV-2 protein similarity and identity with SARS-CoV and BatCoV RaTG13 proteins can be used as indicators of virus origin","volume":"12","author":"Mohammed","year":"2021","journal-title":"J Protein Proteonomics"},{"key":"10.1016\/j.apsb.2026.06.017_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2024.1415885","article-title":"Molecular characterization of SARS-CoV-2 nucleocapsid protein","volume":"14","author":"Huang","year":"2024","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.apsb.2026.06.017_bib43","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/s43556-020-00001-4","article-title":"Structural characterization of the C-terminal domain of SARS-CoV-2 nucleocapsid protein","volume":"1","author":"Zhou","year":"2020","journal-title":"Mol Biomed"},{"key":"10.1016\/j.apsb.2026.06.017_bib44","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1126\/science.abb2762","article-title":"Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2","volume":"367","author":"Yan","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.06.017_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2020.02.052","article-title":"SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor","volume":"181","author":"Hoffmann","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.017_bib46","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1038\/s41586-022-04479-6","article-title":"SARS-CoV-2 omicron variant replication in human bronchus and lung ex vivo","volume":"603","author":"Hui","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.017_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcp.2024.101973","article-title":"SARS-CoV-2 replication and drug discovery","volume":"77","author":"Nazir","year":"2024","journal-title":"Mol Cell Probes"},{"key":"10.1016\/j.apsb.2026.06.017_bib48","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41579-020-00468-6","article-title":"Coronavirus biology and replication: implications for SARS-CoV-2","volume":"19","author":"V\u2019kovski","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2026.06.017_bib49","doi-asserted-by":"crossref","DOI":"10.2807\/1560-7917.ES.2020.26.1.2002106","article-title":"Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020","volume":"26","author":"Leung","year":"2021","journal-title":"Euro Surveill"},{"key":"10.1016\/j.apsb.2026.06.017_bib50","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2109905118","article-title":"Furin cleavage of the SARS-CoV-2 spike is modulated by O-glycosylation","volume":"118","author":"Zhang","year":"2021","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.06.017_bib51","first-page":"52","article-title":"Genetic characteristics and phylogeny of 969-bp S gene sequence of SARS-CoV-2 from Hawai\u2018i reveals the worldwide emerging P681H mutation","volume":"80","author":"Maison","year":"2021","journal-title":"Hawaii J Health Soc Welf"},{"key":"10.1016\/j.apsb.2026.06.017_bib52","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109292","article-title":"Recurrent emergence of SARS-CoV-2 spike deletion H69\/V70 and its role in the Alpha variant B.1.1.7","volume":"35","author":"Meng","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2026.06.017_bib53","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1038\/s41586-021-03402-9","article-title":"Detection of a SARS-CoV-2 variant of concern in South Africa","volume":"592","author":"Tegally","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.017_bib54","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1007\/s00705-022-05365-2","article-title":"The ins and outs of SARS-CoV-2 variants of concern (VOCs)","volume":"167","author":"Salehi-Vaziri","year":"2022","journal-title":"Arch Virol"},{"key":"10.1016\/j.apsb.2026.06.017_bib55","doi-asserted-by":"crossref","first-page":"6559","DOI":"10.1038\/s41467-021-26803-w","article-title":"SARS-CoV-2 B.1.1.7 (Alpha) and B.1.351 (Beta) variants induce pathogenic patterns in K18-hACE2 transgenic mice distinct from early strains","volume":"12","author":"Radvak","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.017_bib56","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2021.02.037","article-title":"Evidence of escape of SARS-CoV-2 variant B.1.351 from natural and vaccine-induced sera","volume":"184","author":"Zhou","year":"2021","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.017_bib57","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1038\/s41576-021-00408-x","article-title":"The biological and clinical significance of emerging SARS-CoV-2 variants","volume":"22","author":"Tao","year":"2021","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.apsb.2026.06.017_bib58","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1126\/science.abf2303","article-title":"Structural impact on SARS-CoV-2 spike protein by D614G substitution","volume":"372","author":"Zhang","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.06.017_bib59","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.3201\/eid2704.210138","article-title":"Novel SARS-CoV-2 variant in travelers from Brazil to Japan","volume":"27","author":"Fujino","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"10.1016\/j.apsb.2026.06.017_bib60","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.jinf.2021.03.013","article-title":"Discovery of a SARS-CoV-2 variant from the P.1 lineage harboring K417T\/E484K\/N501Y mutations in Kofu, Japan","volume":"82","author":"Hirotsu","year":"2021","journal-title":"J Infect"},{"key":"10.1016\/j.apsb.2026.06.017_bib61","doi-asserted-by":"crossref","DOI":"10.1016\/j.chom.2021.04.007","article-title":"Increased resistance of SARS-CoV-2 variant P.1 to antibody neutralization","volume":"29","author":"Wang","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.apsb.2026.06.017_bib62","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1126\/science.abh2644","article-title":"Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus, Brazil","volume":"372","author":"Faria","year":"2021","journal-title":"Science"},{"key":"10.1016\/j.apsb.2026.06.017_bib63","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.3390\/vaccines10101751","article-title":"Variants of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and vaccine effectiveness","volume":"10","author":"Tulimilli","year":"2022","journal-title":"Vaccines"},{"key":"10.1016\/j.apsb.2026.06.017_bib64","doi-asserted-by":"crossref","first-page":"778","DOI":"10.3390\/clinpract11040093","article-title":"Analysis of the Delta variant B.1.617.2 COVID-19","volume":"11","author":"Shiehzadegan","year":"2021","journal-title":"Clin Pract"},{"key":"10.1016\/j.apsb.2026.06.017_bib65","doi-asserted-by":"crossref","DOI":"10.1080\/21645515.2022.2068883","article-title":"Delta variant (B.1.617.2) of SARS-CoV-2: mutations, impact, challenges and possible solutions","volume":"18","author":"Dhawan","year":"2022","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.apsb.2026.06.017_bib66","article-title":"Omicron: a highly transmissible SARS-CoV-2 variant","volume":"27","author":"Rahimi","year":"2022","journal-title":"Gene Rep"},{"key":"10.1016\/j.apsb.2026.06.017_bib67","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.1002\/jmv.27516","article-title":"Sequence analysis of the emerging SARS-CoV-2 variant Omicron in South Africa","volume":"94","author":"Wang","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.apsb.2026.06.017_bib68","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1016\/S0140-6736(21)02758-6","article-title":"Omicron SARS-CoV-2 variant: a new chapter in the COVID-19 pandemic","volume":"398","author":"Karim","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.apsb.2026.06.017_bib69","doi-asserted-by":"crossref","DOI":"10.1002\/ctm2.685","article-title":"The Omicron variant of SARS-CoV-2: understanding the known and living with unknowns","volume":"11","author":"Ingraham","year":"2021","journal-title":"Clin Transl Med"},{"key":"10.1016\/j.apsb.2026.06.017_bib70","doi-asserted-by":"crossref","first-page":"184","DOI":"10.3390\/v16020184","article-title":"Evolution of the SARS-CoV-2 omicron variants: genetic impact on viral fitness","volume":"16","author":"Liu","year":"2024","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2026.06.017_bib71","article-title":"Evaluation of the evolution of SARS-CoV-2 omicron variant and the spreading of LP. 8.1 and NB. 1.8. 1","author":"Yi","year":"2025","journal-title":"medRxiv"},{"key":"10.1016\/j.apsb.2026.06.017_bib72","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1002\/jmv.27558","article-title":"Mutational and phylogenetic analyses of the two lineages of the Omicron variant","volume":"94","author":"Majumdar","year":"2022","journal-title":"J Med Virol"},{"key":"10.1016\/j.apsb.2026.06.017_bib73","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.05.014","article-title":"Potent cross-reactive antibodies following Omicron breakthrough in vaccinees","volume":"185","author":"Nutalai","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.017_bib74","doi-asserted-by":"crossref","DOI":"10.1002\/jgm.3435","article-title":"OMICRON: virology, immunopathogenesis, and laboratory diagnosis","volume":"24","author":"Bazargan","year":"2022","journal-title":"J Gene Med"},{"key":"10.1016\/j.apsb.2026.06.017_bib75","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ijid.2022.06.039","article-title":"Classification of Omicron BA.1, BA.1.1, and BA.2 sublineages by TaqMan assay consistent with whole genome analysis data","volume":"122","author":"Hirotsu","year":"2022","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.apsb.2026.06.017_bib76","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.04.035","article-title":"Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike","volume":"185","author":"Yamasoba","year":"2022","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.017_bib77","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.3390\/v14112401","article-title":"Rapid identification of SARS-CoV-2 Omicron BA.5 spike mutation F486V in clinical specimens using a high-resolution melting-based assay","volume":"14","author":"Aoki","year":"2022","journal-title":"Viruses"},{"key":"10.1016\/j.apsb.2026.06.017_bib78","article-title":"Editorial: the XBB.1.5 (Kraken) subvariant of Omicron SARS-CoV-2 and its rapid global spread","volume":"29","author":"Parums","year":"2023","journal-title":"Med Sci Monit"},{"key":"10.1016\/j.apsb.2026.06.017_bib79","article-title":"The JN.1 variant of COVID-19: immune evasion, transmissibility, and implications for global health","volume":"12","author":"Naveed Siddiqui","year":"2025","journal-title":"Ther Adv Infect Dis"},{"key":"10.1016\/j.apsb.2026.06.017_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.virol.2025.110508","article-title":"Recent SARS-CoV-2 evolution trajectories indicate the emergence of Omicron's several subvariants and the current rise of KP.3.1.1 and XEC","volume":"607","author":"Chakraborty","year":"2025","journal-title":"Virology"},{"key":"10.1016\/j.apsb.2026.06.017_bib81","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmni.2024.101520","article-title":"Genetic variability of the recombinant SARS-CoV-2 XEC: is it a new evolutionary dead-end lineage?","volume":"62","author":"Branda","year":"2024","journal-title":"New Microbes New Infect"},{"key":"10.1016\/j.apsb.2026.06.017_bib82","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-025-15979-6","article-title":"SARS-CoV-2 spike mutations alter structure and energetics to modulate ACE2 binding immune evasion and viral adaptation","volume":"15","author":"Ataya","year":"2025","journal-title":"Sci Rep"},{"key":"10.1016\/j.apsb.2026.06.017_bib83","doi-asserted-by":"crossref","DOI":"10.1016\/j.jinf.2024.106121","article-title":"Molecular insights into the adaptive evolution of SARS-CoV-2 spike protein","volume":"88","author":"Yao","year":"2024","journal-title":"J Infect"},{"key":"10.1016\/j.apsb.2026.06.017_bib84","doi-asserted-by":"crossref","DOI":"10.1128\/mSphere.00480-21","article-title":"Emergence of multiple SARS-CoV-2 antibody escape variants in an immunocompromised host undergoing convalescent plasma treatment","volume":"6","author":"Chen","year":"2021","journal-title":"mSphere"},{"key":"10.1016\/j.apsb.2026.06.017_bib85","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41579-021-00573-0","article-title":"SARS-CoV-2 variants, spike mutations and immune escape","volume":"19","author":"Harvey","year":"2021","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.apsb.2026.06.017_bib86","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.69091","article-title":"N501Y mutation of spike protein in SARS-CoV-2 strengthens its binding to receptor ACE2","volume":"10","author":"Tian","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.apsb.2026.06.017_bib87","doi-asserted-by":"crossref","first-page":"6013","DOI":"10.1038\/s41467-020-19808-4","article-title":"SARS-CoV-2 spike-protein D614G mutation increases virion spike density and infectivity","volume":"11","author":"Zhang","year":"2020","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.017_bib88","doi-asserted-by":"crossref","first-page":"1124","DOI":"10.1016\/j.chom.2021.06.006","article-title":"SARS-CoV-2 spike L452R variant evades cellular immunity and increases infectivity","volume":"29","author":"Motozono","year":"2021","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.apsb.2026.06.017_bib89","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2022.110829","article-title":"Delta spike P681R mutation enhances SARS-CoV-2 fitness over Alpha variant","volume":"39","author":"Liu","year":"2022","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2026.06.017_bib90","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1038\/s41586-021-04266-9","article-title":"Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation","volume":"602","author":"Saito","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.017_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104561","article-title":"SARS-CoV-2 Delta variants, spike-P681R and D950N promote membrane fusion, spike-P681R enhances spike cleavage, but neither substitution affects pathogenicity in hamsters","volume":"91","author":"Furusawa","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.apsb.2026.06.017_bib92","doi-asserted-by":"crossref","first-page":"1603","DOI":"10.3389\/fimmu.2017.01603","article-title":"Nanobodies and nanobody-based human heavy chain antibodies as antitumor therapeutics","volume":"8","author":"Bannas","year":"2017","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.06.017_bib93","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.molmed.2022.08.007","article-title":"Nanobodies as a powerful platform for biomedicine","volume":"28","author":"Shen","year":"2022","journal-title":"Trends Mol Med"},{"key":"10.1016\/j.apsb.2026.06.017_bib94","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.3390\/ijms24065994","article-title":"NANOBODIES\u00ae: a review of diagnostic and therapeutic applications","volume":"24","author":"Jin","year":"2023","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.apsb.2026.06.017_bib95","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1146\/annurev-animal-021419-083831","article-title":"Applications of nanobodies","volume":"9","author":"Muyldermans","year":"2021","journal-title":"Ann Rev Anim Biosci"},{"key":"10.1016\/j.apsb.2026.06.017_bib96","doi-asserted-by":"crossref","first-page":"602","DOI":"10.3390\/ph14070602","article-title":"CPPs to the test: effects on binding, uptake and biodistribution of a tumor targeting nanobody","volume":"14","author":"Collado","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.apsb.2026.06.017_bib97","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1146\/annurev-biochem-063011-092449","article-title":"Nanobodies: natural single-domain antibodies","volume":"82","author":"Muyldermans","year":"2013","journal-title":"Annu Rev Biochem"},{"key":"10.1016\/j.apsb.2026.06.017_bib98","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1039\/D1CB00023C","article-title":"Nanobodies as in vivo, non-invasive, imaging agents","volume":"2","author":"Harmand","year":"2021","journal-title":"RSC Chem Biol"},{"key":"10.1016\/j.apsb.2026.06.017_bib99","doi-asserted-by":"crossref","DOI":"10.3389\/fncel.2020.573278","article-title":"Nanobody-based probes for subcellular protein identification and visualization","volume":"14","author":"de Beer","year":"2020","journal-title":"Front Cell Neurosci"},{"key":"10.1016\/j.apsb.2026.06.017_bib100","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1186\/s12951-024-02900-y","article-title":"Discovery of nanobodies: a comprehensive review of their applications and potential over the past five years","volume":"22","author":"Alexander","year":"2024","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.apsb.2026.06.017_bib101","doi-asserted-by":"crossref","first-page":"2084","DOI":"10.1111\/febs.15515","article-title":"A guide to: generation and design of nanobodies","volume":"288","author":"Muyldermans","year":"2021","journal-title":"FEBS J"},{"key":"10.1016\/j.apsb.2026.06.017_bib102","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2025.2486390","article-title":"Nanoscale warriors against viral invaders: a comprehensive review of nanobodies as potential antiviral therapeutics","volume":"17","author":"Verma","year":"2025","journal-title":"mAbs"},{"key":"10.1016\/j.apsb.2026.06.017_bib103","doi-asserted-by":"crossref","DOI":"10.1016\/j.slasd.2025.100251","article-title":"Nanobodies: a new frontier in antiviral therapies","volume":"35","author":"Mohammed","year":"2025","journal-title":"SLAS Discov"},{"key":"10.1016\/j.apsb.2026.06.017_bib104","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12964-025-02270-4","article-title":"Nanobodies and their derivatives: pioneering the future of cancer immunotherapy","volume":"23","author":"Li","year":"2025","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.apsb.2026.06.017_bib105","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1039\/D5NH00283D","article-title":"Small but mighty: the versatility of nanobodies in modern medicine","volume":"10","author":"Blueggel","year":"2025","journal-title":"Nanoscale Horiz"},{"key":"10.1016\/j.apsb.2026.06.017_bib106","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.3390\/microorganisms13061352","article-title":"Research progress on the application of neutralizing nanobodies in the prevention and treatment of viral infections","volume":"13","author":"Duan","year":"2025","journal-title":"Microorganisms"},{"key":"10.1016\/j.apsb.2026.06.017_bib107","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2025.115368","article-title":"Nanobodies targeting cytokines for the amelioration of autoimmune diseases","volume":"164","author":"Vijayandran","year":"2025","journal-title":"Int Immunopharmacol"},{"key":"10.1016\/j.apsb.2026.06.017_bib108","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1080\/14712598.2023.2231344","article-title":"Ozoralizumab: first nanobody\u00ae therapeutic for rheumatoid arthritis","volume":"23","author":"Tanaka","year":"2023","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.apsb.2026.06.017_bib109","doi-asserted-by":"crossref","first-page":"3731","DOI":"10.1007\/s00259-024-06808-5","article-title":"Synthesis, preclinical evaluation and pilot clinical translation of [68Ga]Ga-PMD22, a novel nanobody PET probe targeting CLDN18.2 of gastrointestinal cancer","volume":"51","author":"Wang","year":"2024","journal-title":"Eur J Nucl Med Mol Imag"},{"key":"10.1016\/j.apsb.2026.06.017_bib110","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1158\/1078-0432.CCR-21-4097","article-title":"Autologous nanobody-derived fratricide-resistant CD7-CAR T-cell therapy for patients with relapsed and refractory T-cell acute lymphoblastic leukemia\/lymphoma","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.apsb.2026.06.017_bib111","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1182\/blood.2024024861","article-title":"Nanobody-based naturally selected CD7-targeted CAR-T therapy for acute myeloid leukemia","volume":"145","author":"Lu","year":"2025","journal-title":"Blood"},{"key":"10.1016\/j.apsb.2026.06.017_bib112","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1056\/NEJMoa1505533","article-title":"Caplacizumab for acquired thrombotic thrombocytopenic purpura","volume":"374","author":"Peyvandi","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.apsb.2026.06.017_bib113","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01461-2024","article-title":"A proof-of-mechanism trial in asthma with lunsekimig, a bispecific NANOBODY molecule","volume":"65","author":"Deiteren","year":"2025","journal-title":"Eur Respir J"},{"key":"10.1016\/j.apsb.2026.06.017_bib114","doi-asserted-by":"crossref","first-page":"7898","DOI":"10.1038\/s41467-024-51745-4","article-title":"A single-domain antibody targeting factor XII inhibits both thrombosis and inflammation","volume":"15","author":"Xu","year":"2024","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.017_bib115","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01448-23","article-title":"Discovery of Nanosota-2, -3, and -4 as super potent and broad-spectrum therapeutic nanobody candidates against COVID-19","volume":"97","author":"Ye","year":"2023","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2026.06.017_bib116","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1346328","article-title":"Serum immunoglobulin or albumin binding single-domain antibodies that enable tailored half-life extension of biologics in multiple animal species","volume":"15","author":"Harmsen","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.06.017_bib117","doi-asserted-by":"crossref","DOI":"10.1002\/anbr.202400214","article-title":"Long-circulating nanobody confers durable prophylaxis against severe acute respiratory syndrome coronavirus 2 omicron infection","volume":"5","author":"Vaskuri","year":"2025","journal-title":"Adv Nanobiomed Res"},{"key":"10.1016\/j.apsb.2026.06.017_bib118","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmc.2025.118319","article-title":"Engineered B7-H3-targeted VHH-Fc fusion antibody demonstrates rapid tumor accumulation for infrared imaging in pancreatic cancer xenograft model","volume":"129","author":"Mo","year":"2025","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.apsb.2026.06.017_bib119","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2024.09.043","article-title":"Adaptive multi-epitope targeting and avidity-enhanced nanobody platform for ultrapotent, durable antiviral therapy","volume":"187","author":"Xiang","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.apsb.2026.06.017_bib120","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01285-25","article-title":"A novel bispecific nanobody protects mice against RSV infection via intranasal administration","volume":"99","author":"Zhang","year":"2025","journal-title":"J Virol"},{"key":"10.1016\/j.apsb.2026.06.017_bib121","doi-asserted-by":"crossref","first-page":"5831","DOI":"10.1038\/s41467-025-60232-3","article-title":"Single-domain antibodies directed against hemagglutinin and neuraminidase protect against influenza B viruses","volume":"16","author":"Matthys","year":"2025","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.017_bib122","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1021\/acsptsci.3c00042","article-title":"Emerging landscape of nanobodies and their neutralizing applications against SARS-CoV-2 virus","volume":"6","author":"Feng","year":"2023","journal-title":"ACS Pharmacol Transl Sci"},{"key":"10.1016\/j.apsb.2026.06.017_bib123","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2021.129974","article-title":"Nanobodies as powerful pulmonary targeted biotherapeutics against SARS-CoV-2, pharmaceutical point of view","volume":"1865","author":"Najmeddin","year":"2021","journal-title":"Biochim Biophys Acta Gen Subj"},{"key":"10.1016\/j.apsb.2026.06.017_bib124","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2022.103960","article-title":"A potent alpaca-derived nanobody that neutralizes SARS-CoV-2 variants","volume":"25","author":"Weinstein","year":"2022","journal-title":"iScience"},{"key":"10.1016\/j.apsb.2026.06.017_bib125","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2201433119","article-title":"Dromedary camel nanobodies broadly neutralize SARS-CoV-2 variants","volume":"119","author":"Hong","year":"2022","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.apsb.2026.06.017_bib126","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1038\/s41590-020-0778-2","article-title":"SARS-CoV-2 infection of human ACE2-transgenic mice causes severe lung inflammation and impaired function","volume":"21","author":"Winkler","year":"2020","journal-title":"Nat Immunol"},{"key":"10.1016\/j.apsb.2026.06.017_bib127","doi-asserted-by":"crossref","first-page":"944","DOI":"10.1038\/s41467-021-21239-8","article-title":"Post-exposure protection of SARS-CoV-2 lethal infected K18-hACE2 transgenic mice by neutralizing human monoclonal antibody","volume":"12","author":"Rosenfeld","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.017_bib128","doi-asserted-by":"crossref","first-page":"3537","DOI":"10.1038\/s41467-023-39267-x","article-title":"Discovery and characterization of potent pan-variant SARS-CoV-2 neutralizing antibodies from individuals with omicron breakthrough infection","volume":"14","author":"Guo","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.017_bib129","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1038\/s41586-021-03720-y","article-title":"In vivo monoclonal antibody efficacy against SARS-CoV-2 variant strains","volume":"596","author":"Chen","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.017_bib130","doi-asserted-by":"crossref","first-page":"129","DOI":"10.3390\/vaccines12020129","article-title":"Serial llama immunization with various SARS-CoV-2 RBD variants induces broad spectrum virus-neutralizing nanobodies","volume":"12","author":"Solodkov","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.apsb.2026.06.017_bib131","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1038\/s41467-023-36106-x","article-title":"Shark nanobodies with potent SARS-CoV-2 neutralizing activity and broad sarbecovirus reactivity","volume":"14","author":"Chen","year":"2023","journal-title":"Nat Commun"},{"key":"10.1016\/j.apsb.2026.06.017_bib132","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202154199","article-title":"Biparatopic sybodies neutralize SARS-CoV-2 variants of concern and mitigate drug resistance","volume":"23","author":"Walter","year":"2022","journal-title":"EMBO Rep"},{"key":"10.1016\/j.apsb.2026.06.017_bib133","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272364","article-title":"A humanized nanobody phage display library yields potent binders of SARS CoV-2 spike","volume":"17","author":"Fu","year":"2022","journal-title":"PLoS One"},{"key":"10.1016\/j.apsb.2026.06.017_bib134","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1038\/s41586-021-03676-z","article-title":"Nanobodies from camelid mice and llamas neutralize SARS-CoV-2 variants","volume":"595","author":"Xu","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.apsb.2026.06.017_bib135","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012726","article-title":"Discovery of Nanosota-9 as Anti-Omicron nanobody therapeutic candidate","volume":"20","author":"Ye","year":"2024","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.apsb.2026.06.017_bib136","doi-asserted-by":"crossref","first-page":"417","DOI":"10.3390\/vaccines12040417","article-title":"Engineered multivalent nanobodies efficiently neutralize SARS-CoV-2 Omicron subvariants BA.1, BA.4\/5, XBB.1 and BQ.1.1","volume":"12","author":"Wang","year":"2024","journal-title":"Vaccines"},{"key":"10.1016\/j.apsb.2026.06.017_bib137","doi-asserted-by":"crossref","DOI":"10.1098\/rsob.230252","article-title":"Structural and functional characterization of nanobodies that neutralize Omicron variants of SARS-CoV-2","volume":"14","author":"Cornish","year":"2024","journal-title":"Open Biol"},{"key":"10.1016\/j.apsb.2026.06.017_bib138","doi-asserted-by":"crossref","first-page":"3866","DOI":"10.1021\/acs.molpharmaceut.4c00165","article-title":"Development of broad-spectrum nanobodies for the therapy and diagnosis of SARS-CoV-2 and its multiple variants","volume":"21","author":"He","year":"2024","journal-title":"Mol Pharm"},{"key":"10.1016\/j.apsb.2026.06.017_bib139","doi-asserted-by":"crossref","DOI":"10.1002\/jmv.29528","article-title":"A panel of multivalent nanobodies broadly neutralizing Omicron subvariants and recombinant","volume":"96","author":"Zheng","year":"2024","journal-title":"J Med Virol"},{"key":"10.1016\/j.apsb.2026.06.017_bib140","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2023.105778","article-title":"Nanobodies to multiple spike variants and inhalation of nanobody-containing aerosols neutralize SARS-CoV-2 in cell culture and hamsters","volume":"221","author":"Aksu","year":"2024","journal-title":"Antivir Res"},{"key":"10.1016\/j.apsb.2026.06.017_bib141","article-title":"A potent and broad-spectrum neutralizing nanobody for SARS-CoV-2 viruses, including all major Omicron strains","volume":"4","author":"Yao","year":"2023","journal-title":"MedComm (2020)"},{"key":"10.1016\/j.apsb.2026.06.017_bib142","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1012625","article-title":"Super broad and protective nanobodies against sarbecoviruses including SARS-CoV-1 and the divergent SARS-CoV-2 subvariant KP.3.1.1","volume":"20","author":"Dong","year":"2024","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.apsb.2026.06.017_bib143","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-024-01847-8","article-title":"Enhanced potency of an IgM-like nanobody targeting conserved epitope in SARS-CoV-2 spike N-terminal domain","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.06.017_bib144","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1038\/s42003-022-03866-z","article-title":"Arsenal of nanobodies shows broad-spectrum neutralization against SARS-CoV-2 variants of concern in vitro and in vivo in hamster models","volume":"5","author":"Rossotti","year":"2022","journal-title":"Commun Biol"},{"key":"10.1016\/j.apsb.2026.06.017_bib145","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1016\/j.scib.2023.03.027","article-title":"A broadly neutralizing nanobody targeting the highly conserved S2 subunit of sarbecoviruses","volume":"68","author":"Wang","year":"2023","journal-title":"Sci Bull"},{"key":"10.1016\/j.apsb.2026.06.017_bib146","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/s12951-025-03150-2","article-title":"A shark-derived broadly neutralizing nanobody targeting a highly conserved epitope on the S2 domain of sarbecoviruses","volume":"23","author":"Feng","year":"2025","journal-title":"J Nanobiotechnol"},{"key":"10.1016\/j.apsb.2026.06.017_bib147","doi-asserted-by":"crossref","DOI":"10.1096\/fj.202202099RR","article-title":"Identification of nurse shark VNAR single-domain antibodies targeting the spike S2 subunit of SARS-CoV-2","volume":"37","author":"Buffington","year":"2023","journal-title":"FASEB J"},{"key":"10.1016\/j.apsb.2026.06.017_bib148","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.73027","article-title":"Highly synergistic combinations of nanobodies that target SARS-CoV-2 and are resistant to escape","volume":"10","author":"Mast","year":"2021","journal-title":"eLife"},{"key":"10.1016\/j.apsb.2026.06.017_bib149","doi-asserted-by":"crossref","DOI":"10.1016\/j.omtn.2024.102304","article-title":"Nanobody against SARS-CoV-2 non-structural protein Nsp9 inhibits viral replication in human airway epithelia","volume":"35","author":"Venit","year":"2024","journal-title":"Mol Ther Nucleic Acids"},{"key":"10.1016\/j.apsb.2026.06.017_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1220477","article-title":"A highly sensitive nanobody-based immunoassay detecting SARS-CoV-2 nucleocapsid protein using all-recombinant reagents","volume":"14","author":"Segovia-de Los Santos","year":"2023","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.06.017_bib151","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.3390\/biom15111489","article-title":"Structural insights into the SARS-CoV-2 spike protein and its implications for antibody resistance","volume":"15","author":"Yamamoto","year":"2025","journal-title":"Biomolecules"},{"key":"10.1016\/j.apsb.2026.06.017_bib152","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41392-022-00912-4","article-title":"An ultrapotent RBD-targeted biparatopic nanobody neutralizes broad SARS-CoV-2 variants","volume":"7","author":"Chi","year":"2022","journal-title":"Signal Transduct Targeted Ther"},{"key":"10.1016\/j.apsb.2026.06.017_bib153","doi-asserted-by":"crossref","DOI":"10.15252\/embr.202153865","article-title":"Biparatopic nanobodies protect mice from lethal challenge with SARS-CoV-2 variants of concern","volume":"23","author":"Wagner","year":"2022","journal-title":"EMBO Rep"},{"key":"10.1016\/j.apsb.2026.06.017_bib154","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.822159","article-title":"Single-domain antibodies efficiently neutralize SARS-CoV-2 variants of concern","volume":"13","author":"Favorskaya","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.apsb.2026.06.017_bib155","article-title":"Engineered multivalent nanobodies potently and broadly neutralize SARS-CoV-2 variants","volume":"4","author":"Zupancic","year":"2021","journal-title":"Adv Ther"},{"key":"10.1016\/j.apsb.2026.06.017_bib156","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/s41422-022-00700-3","article-title":"Hetero-bivalent nanobodies provide broad-spectrum protection against SARS-CoV-2 variants of concern including Omicron","volume":"32","author":"Ma","year":"2022","journal-title":"Cell Res"},{"key":"10.1016\/j.apsb.2026.06.017_bib157","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109869","article-title":"A potent bispecific nanobody protects hACE2 mice against SARS-CoV-2 infection via intranasal administration","volume":"37","author":"Wu","year":"2021","journal-title":"Cell Rep"},{"key":"10.1016\/j.apsb.2026.06.017_bib158","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1186\/s11671-025-04200-2","article-title":"Trends in nanobody technology in industrialization","volume":"20","author":"Wu","year":"2025","journal-title":"Discov Nano"},{"key":"10.1016\/j.apsb.2026.06.017_bib159","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1007\/s40265-018-0989-0","article-title":"Caplacizumab: first global approval","volume":"78","author":"Duggan","year":"2018","journal-title":"Drugs"},{"key":"10.1016\/j.apsb.2026.06.017_bib160","doi-asserted-by":"crossref","DOI":"10.1016\/j.trac.2025.118526","article-title":"Modern strategies in nanobody engineering and functionalization: from discovery to biosensing application","volume":"194","author":"Wang","year":"2026","journal-title":"TrAC Trends Anal Chem"},{"key":"10.1016\/j.apsb.2026.06.017_bib161","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1111\/febs.15809","article-title":"Immunogenicity and humanization of single-domain antibodies","volume":"289","author":"Rossotti","year":"2022","journal-title":"FEBS J"},{"key":"10.1016\/j.apsb.2026.06.017_bib162","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2022.963978","article-title":"Research progress and applications of nanobody in human infectious diseases","volume":"13","author":"Mei","year":"2022","journal-title":"Front Pharmacol"}],"container-title":["Acta Pharmaceutica Sinica B"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526003461?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211383526003461?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T20:02:10Z","timestamp":1786219330000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211383526003461"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":161,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2211383526003461"],"URL":"https:\/\/doi.org\/10.1016\/j.apsb.2026.06.017","relation":{},"ISSN":["2211-3835"],"issn-type":[{"value":"2211-3835","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nanobodies targeting SARS-CoV-2 variants","name":"articletitle","label":"Article Title"},{"value":"Acta Pharmaceutica Sinica B","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.apsb.2026.06.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V. on behalf of Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences.","name":"copyright","label":"Copyright"}]}}